{
    "clinical_study": {
        "@rank": "35165", 
        "arm_group": [
            {
                "arm_group_label": "Omeprazole 20mg aqueous", 
                "arm_group_type": "Active Comparator", 
                "description": "Treatment A: a single oral dose of omeprazole 20-mg aqueous-solvent based capsules (AstraZeneca - test)"
            }, 
            {
                "arm_group_label": "Omeprazole 20mg organic", 
                "arm_group_type": "Active Comparator", 
                "description": "Treatment B: a single oral dose of omeprazole 20-mg organic-solvent based capsules (Merck - reference for Treatment A)"
            }, 
            {
                "arm_group_label": "Omeprazole 40mg aqueous", 
                "arm_group_type": "Active Comparator", 
                "description": "Treatment C: a single dose of omeprazole 40-mg aqueous-solvent based capsules (AstraZeneca - test)"
            }, 
            {
                "arm_group_label": "Omeprazole 40mg organic", 
                "arm_group_type": "Active Comparator", 
                "description": "Treatment D: a single dose of omeprazole 40-mg organic-solvent based capsules (Merck - reference for Treatment C)"
            }
        ], 
        "brief_summary": {
            "textblock": "This is  An Open-label, Randomized, Single-center, 4-way Crossover, Single dose\n      Bioequivalence Study Comparing Omeprazole 20 and 40-mg Aqueous solvent Based Capsules\n      Manufactured by AstraZeneca with Omeprazole 20 and 40-mg Organic-solvent Based Capsules\n      Manufactured by Merck"
        }, 
        "brief_title": "Prilosec Bioequivalence Study in Healthy Volunteers", 
        "completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "condition": "Bioequivalence, AUC, Cmax, Pharmacokinetics", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy male and female volunteers aged 18 to 50 years, inclusive, with suitable\n             veins for cannulation or repeated venepuncture.\n\n          -  Female could be of nonchildbearing potential (postmenopausal or irreversible surgical\n             sterilization) and childbearing potential (negative pregnancy test at screening and\n             use 2 effective methods of avoiding pregnancy).\n\n          -  Have a body mass index (BMI) between 18 and 30 kg/m2, inclusive, and a weight of at\n             least 50 kg and no more than 100 kg, inclusive.\n\n        Exclusion Criteria:\n\n          -  History of any clinically important disease or disorder which, in the opinion of the\n             Investigator, may either put the volunteer at risk because of participation in the\n             study.\n\n          -  History or presence of gastrointestinal, hepatic, or renal disease or any other\n             condition known to interfere with absorption, distribution, metabolism, or excretion\n             of drugs.\n\n          -  Any clinically important illness, medical/surgical procedure, or trauma within 4\n             weeks of the first administration of investigational medicinal product (IMP).\n\n          -  Any clinically significant abnormalities in the physical examination, clinical\n             laboratory values, 12-lead ECG, or vital signs, as judged by the Investigator.\n\n          -  Moderate to heavy smokers (more than 10 cigarettes per day or equivalent in\n             tobacco-containing products)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "54", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 5, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01921920", 
            "org_study_id": "D9584C00010"
        }, 
        "intervention": {
            "arm_group_label": [
                "Omeprazole 20mg aqueous", 
                "Omeprazole 20mg organic", 
                "Omeprazole 40mg aqueous", 
                "Omeprazole 40mg organic"
            ], 
            "description": "Omeprazole 20 mg (AstraZeneca - test) Omeprazole 40 mg (AstraZeneca - test) Omeprazole 20 (Merck - reference) Omeprazole 40mg (Merck - reference)", 
            "intervention_name": "Omeprazole", 
            "intervention_type": "Drug", 
            "other_name": "Prilosec"
        }, 
        "intervention_browse": {
            "mesh_term": "Omeprazole"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": "Omeprazole, Prilosec, Phase I, Healthy Subjects, Pharmacokinetics, Bioequivalence", 
        "lastchanged_date": "November 21, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Overland Park", 
                    "country": "United States", 
                    "state": "Kansas"
                }, 
                "name": "Research Site"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "An Open-label, Randomized, Single-center, 4-way Crossover, Single Dose Bioequivalence Study Comparing Omeprazole 20 and 40-mg Aqueous Solvent Based Capsules Manufactured by AstraZeneca With Omeprazole 20 and 40-mg Organic-solvent Based Capsules Manufactured by Merck", 
        "overall_official": [
            {
                "affiliation": "Quintiles Phase I unit, Kansas", 
                "last_name": "David Mathews, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "AstraZeneca", 
                "last_name": "Helen Lunde, MD", 
                "role": "Study Director"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "AUC", 
                "measure": "Bioequivalence of omeprazole 20-mg aqueous-solvent based capsules versus omeprazole 20-mg organic solvent based capsules", 
                "safety_issue": "No", 
                "time_frame": "predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, and 10 hours postdose."
            }, 
            {
                "description": "AUC", 
                "measure": "Bioequivalence of omeprazole 40-mg aqueous-solvent based capsules versus omeprazole 40-mg organic solvent based capsules", 
                "safety_issue": "No", 
                "time_frame": "predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, and 10 hours postdose."
            }, 
            {
                "description": "AUC (0-t)", 
                "measure": "Bioequivalence of omeprazole 20-mg aqueous-solvent based capsules versus omeprazole 20-mg organic solvent based capsules", 
                "safety_issue": "No", 
                "time_frame": "predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, and 10 hours postdose."
            }, 
            {
                "description": "Cmax", 
                "measure": "Bioequivalence of omeprazole 20-mg aqueous-solvent based capsules versus omeprazole 20-mg organic solvent based capsules", 
                "safety_issue": "No", 
                "time_frame": "predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, and 10 hours postdose."
            }, 
            {
                "description": "AUC(0-t)", 
                "measure": "Bioequivalence of omeprazole 40-mg aqueous-solvent based capsules versus omeprazole 40-mg organic solvent based capsules", 
                "safety_issue": "No", 
                "time_frame": "predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, and 10 hours postdose."
            }, 
            {
                "description": "Cmax", 
                "measure": "Bioequivalence of omeprazole 40-mg aqueous-solvent based capsules versus omeprazole 40-mg organic solvent based capsules", 
                "safety_issue": "No", 
                "time_frame": "predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, and 10 hours postdose."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01921920"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Cmax", 
                "measure": "Pharmacokinetics of 2 enteric-coated formulations after a single dose of 20-mg omeprazole", 
                "safety_issue": "No", 
                "time_frame": "predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, and 10 hours postdose."
            }, 
            {
                "description": "Cmax", 
                "measure": "Pharmacokinetics of 2 enteric-coated formulations after a single dose of 40-mg omeprazole", 
                "safety_issue": "No", 
                "time_frame": "predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, and 10 hours postdose."
            }, 
            {
                "description": "t1/2", 
                "measure": "Pharmacokinetics of 2 enteric-coated formulations after a single dose of 20-mg omeprazole", 
                "safety_issue": "No", 
                "time_frame": "predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, and 10 hours postdose."
            }, 
            {
                "description": "tmax", 
                "measure": "Pharmacokinetics of 2 enteric-coated formulations after a single dose of 20-mg omeprazole", 
                "safety_issue": "No", 
                "time_frame": "predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, and 10 hours postdose."
            }, 
            {
                "description": "AUC(0-t)", 
                "measure": "Pharmacokinetics of 2 enteric-coated formulations after a single dose of 20-mg omeprazole", 
                "safety_issue": "No", 
                "time_frame": "predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, and 10 hours postdose."
            }, 
            {
                "description": "AUC", 
                "measure": "Pharmacokinetics of 2 enteric-coated formulations after a single dose of 20-mg omeprazole", 
                "safety_issue": "No", 
                "time_frame": "predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, and 10 hours postdose."
            }, 
            {
                "description": "\u03bbz", 
                "measure": "Pharmacokinetics of 2 enteric-coated formulations after a single dose of 20-mg omeprazole", 
                "safety_issue": "No", 
                "time_frame": "predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, and 10 hours postdose."
            }, 
            {
                "description": "tmax", 
                "measure": "Pharmacokinetics of 2 enteric-coated formulations after a single dose of 40-mg omeprazole", 
                "safety_issue": "No", 
                "time_frame": "predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, and 10 hours postdose."
            }, 
            {
                "description": "AUC(0-t)", 
                "measure": "Pharmacokinetics of 2 enteric-coated formulations after a single dose of 40-mg omeprazole", 
                "safety_issue": "No", 
                "time_frame": "predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, and 10 hours postdose."
            }, 
            {
                "description": "AUC", 
                "measure": "Pharmacokinetics of 2 enteric-coated formulations after a single dose of 40-mg omeprazole", 
                "safety_issue": "No", 
                "time_frame": "predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, and 10 hours postdose."
            }, 
            {
                "description": "\u03bbz", 
                "measure": "Pharmacokinetics of 2 enteric-coated formulations after a single dose of 40-mg omeprazole", 
                "safety_issue": "No", 
                "time_frame": "predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, and 10 hours postdose."
            }, 
            {
                "description": "t1/2", 
                "measure": "Pharmacokinetics of 2 enteric-coated formulations after a single dose of 40-mg omeprazole", 
                "safety_issue": "No", 
                "time_frame": "predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, and 10 hours postdose."
            }
        ], 
        "source": "AstraZeneca", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "AstraZeneca", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}